Literature DB >> 31823331

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.

Yolanda Jerez1,2, Ivan Márquez-Rodas1,2, Inmaculada Aparicio1, Manuel Alva1, Miguel Martín3,4, Sara López-Tarruella1,2.   

Abstract

The poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy. An increasing number of clinical trials are evaluating the role of PARP inhibitors (PARPi) in BC, alone and in combination with other therapies (including immunotherapy), as well as in earlier stages of the disease. This review describes the unique mechanism of action of these drugs and puts into clinical context the results of pivotal clinical trials. We also discuss the future development of PARPi in BC, their potential combination with other strategies, including chemotherapy and immune-checkpoint inhibitors, and the impact of these treatments in current genetic counselling.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31823331     DOI： 10.1007/s40265-019-01235-5

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  62 in total

1.  A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).

Authors:  Nicholas C Turner; Melinda L Telli; Hope S Rugo; Audrey Mailliez; Johannes Ettl; Eva-Maria Grischke; Lida A Mina; Judith Balmaña; Peter A Fasching; Sara A Hurvitz; Andrew M Wardley; Colombe Chappey; Alison L Hannah; Mark E Robson
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

2.  Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Authors:  Minesh P Mehta; Ding Wang; Fen Wang; Lawrence Kleinberg; Anthony Brade; H Ian Robins; Aruna Turaka; Terri Leahy; Diane Medina; Hao Xiong; Nael M Mostafa; Martin Dunbar; Ming Zhu; Jane Qian; Kyle Holen; Vincent Giranda; Walter J Curran
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

3.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Authors:  Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza
Journal:  Lancet Oncol       Date:  2011-08-19       Impact factor: 41.316

Review 4.  Emerging therapeutic modalities of PARP inhibitors in breast cancer.

Authors:  Xin Wang; Yaqin Shi; Doudou Huang; Xiaoxiang Guan
Journal:  Cancer Treat Rev       Date:  2018-05-31       Impact factor: 12.111

5.  Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Authors:  J Ettl; R G W Quek; K-H Lee; H S Rugo; S Hurvitz; A Gonçalves; L Fehrenbacher; R Yerushalmi; L A Mina; M Martin; H Roché; Y-H Im; D Markova; H Bhattacharyya; A L Hannah; W Eiermann; J L Blum; J K Litton
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  The HRD Decision-Which PARP Inhibitor to Use for Whom and When.

Authors:  Elise C Kohn; Jung-Min Lee; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2017-10-03       Impact factor: 12.531

Review 8.  A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.

Authors:  Carol Forbes; Debra Fayter; Shelley de Kock; Ruben Gw Quek
Journal:  Cancer Manag Res       Date:  2019-03-22       Impact factor: 3.989

Review 9.  PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.

Authors:  Man Yee T Keung; Yanyuan Wu; Jaydutt V Vadgama
Journal:  J Clin Med       Date:  2019-03-30       Impact factor: 4.241

10.  Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Authors:  Yvette Drew; Jonathan Ledermann; Geoff Hall; Daniel Rea; Ros Glasspool; Martin Highley; Gordon Jayson; Julieann Sludden; James Murray; David Jamieson; Sarah Halford; Gary Acton; Zoe Backholer; Raffaella Mangano; Alan Boddy; Nicola Curtin; Ruth Plummer
Journal:  Br J Cancer       Date:  2016-03-22       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.